NESP: Phase III

A preliminary analysis of a 522-patient pivotal trial suggested that NESP is safe and effective when given by different routes to both hemodialysis patients and peritoneal dialysis patients. AMGN said that three international Phase III trials of NESP have enrolled the requisite number of patients (>1500 total) and are expected to be completed by the end of 1999. AMGN declined to state the phase of the pivotal trial or whether it was one of the three Phase III studies. ...